U.S. High Court Won’t Rule If Drug Maker Has Duty To Monitor Drug Study Patients

(October 1, 2018, 12:00 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on Oct. 1 said it will not review a California state appeals court ruling that overturned a $5.6 million Risperdal death verdict, preserving a ruling that drug study sponsors owe no duty to monitor the medical condition of persons enrolled in the study (Marion Liu, et al. v. Janssen Research & Development, LLC, No. 18-97, U.S. Sup.)....

Related Sections